Since October 2024, technology for all people living with type 1 diabetes (T1) has been fully funded. In Waikato, 66 per cent of people with T1 are now using Automated Insulin Delivery (AID), also known as insulin pump therapy.
If you have patients with T1 in your practice who are not currently using an insulin pump, we encourage you to discuss the benefits of AID with them and refer them to the Regional Diabetes Service via BPAC for assessment and support with transitioning. Evidence shows that AID can significantly improve quality of life and glycaemic control, without increasing hypoglycaemia, helping to reduce the risk of long-term diabetes-related complications.
For prescribing support, please refer to the T1 consumables prescriber guide for primary care. If you have any questions, contact Kathy Knight, Waikato Clinical Diabetes Specialist.
Kathy joined Pinnacle earlier this month as clinical diabetes specialist for Waikato, replacing the role previously held by Anne Waterman.
Read moreThe Diabetes and Chronic Kidney Disease program aims to slow progression of CKD leading to end-stage renal disease and other diabetes related complications. The aims are achieved by partnering with the patient/whanau, sharing matauranga/knowledge, improving self-management skills and strategies, and enabling appropriate treatment intensification. For people living with suboptimal diabetes (Hbalc greater than 53 mmol/mol) and CKD 3B or earlier (eGFR 30 ml/min and above), please see the referral criteria and pathway for guidance.
Read moreFunding for patients who require a follow-up appointment following HbA1c retest by Awanui Labs.
View detailsA guide for clinical management of type 2 diabetes, to support nurses at all levels to develop their knowledge and clinical reasoning in diabetes care.